Abstract: Clear bioavailable liquid softgel fill compositions comprising a) at least one analgesic and one or more of decongestants, expectorants, antitussives and/or antihistamines; b) a matrix comprising a pharmaceutically acceptable poly(alkylene glycol) and a pharmaceutically acceptable alkylene glycol; c) a solubilizing agent comprising a pharmaceutically acceptable polymeric solubilizing agent and water are disclosed. Also disclosed are methods for the preparation of such clear fill compositions, and softgel capsules containing the clear bioavailable liquid fill composition.

Abstract: The present invention relates to bioavailable fill compositions containing one or more of a decongestant, an expectorant, an antitussive, an analgesic, and/or an antihistamine; capsules filled with the bioavailable fill compositions; and methods of making same.

Abstract: Clear bioavailable liquid softgel fill compositions comprising a) at least one analgesic and one or more of decongestants, expectorants, antitussives and/or antihistamines; b) a matrix comprising a pharmaceutically acceptable poly(alkylene glycol) and a pharmaceutically acceptable alkylene glycol; c) a solubilizing agent comprising a pharmaceutically acceptable polymeric solubilizing agent and water are disclosed. Also disclosed are methods for the preparation of such clear fill compositions, and softgel capsules containing the clear bioavailable liquid fill composition.

Abstract: A method uses an explicit resource file (ERF) to repetitively execute a set of processes using consistent resources. The method generates the ERF for a set of processes. The ERF identifies one or more specified central processing units (CPUs), one or more specified graphics processing units (GPUs), and one or more memory ranges in memory to be used by the one or more specified CPUs and the one or more specified GPUs when executing the set of processes. The method enforces compliance with the ERF when repetitively executing the set of processes.

Abstract: The present invention relates to bioavailable fill compositions containing one or more of a decongestant, an expectorant, an antitussive, an analgesic, and/or an antihistamine; capsules filled with the bioavailable fill compositions; and methods of making same.

Abstract: Clear bioavailable liquid softgel fill compositions comprising a) at least one analgesic and one or more of decongestants, expectorants, antitussives and/or antihistamines; b) a matrix comprising a pharmaceutically acceptable poly(alkylene glycol) and a pharmaceutically acceptable alkylene glycol; c) a solubilizing agent comprising a pharmaceutically acceptable polymeric solubilizing agent and water are disclosed. Also disclosed are methods for the preparation of such clear fill compositions, and softgel capsules containing the clear bioavailable liquid fill composition.

Abstract: Bioavailable liquid softgel fill compositions comprising a) fexofenadine or a fexofenadine salt; b) a matrix comprising a pharmaceutically acceptable poly(alkylene glycol), optionally a pharmaceutically acceptable alkylene glycol, optionally a pharmaceutically acceptable polymeric solubilizing agent, and optionally a pharmaceutically acceptable surfactant; and c) a pharmaceutically acceptable acidulant are disclosed. Also disclosed are methods for the preparation of such fill compositions, and softgel capsules containing the bioavailable liquid fill composition.

Abstract: Stabilized liquid, suspension or gel compositions containing a dialkyl fumarate and comprising a vehicle which serves as a protective base, a pharmaceutically acceptable surfactant, and a pharmaceutically acceptable acidulant, and methods of preparing such compositions are disclosed. Capsules and other dosage forms containing the stabilized liquid, suspension or gel compositions are also disclosed.

Abstract: Bioavailable liquid softgel fill compositions comprising a) fexofenadine or a fexofenadine salt; b) a matrix comprising a pharmaceutically acceptable poly(alkylene glycol), a pharmaceutically acceptable alkylene glycol, a pharmaceutically acceptable polymeric solubilizing agent, and a pharmaceutically acceptable surfactant; and c) a pharmaceutically acceptable acidulant are disclosed. Also disclosed are methods for the preparation of such fill compositions, and softgel capsules containing the bioavailable liquid fill composition.

Abstract: A pharmaceutical formulation contains 10-60% by weight acetaminophen as the only active ingredient and a solvent system for dissolving the acetaminophen. The formulation is free of any ionizing agent and its solvent system includes water, polyethylene glycol, and polyvinylpyrrolidone that is 2-50% by weight and has a molecular weight of 2,000 to 1,500,000. Also disclosed is another acetaminophen formulation containing polyvinylpyrrolidone as high as 25-50% by weight.

Abstract: A pharmaceutical formulation contains 10-60% by weight acetaminophen as the only active ingredient and a solvent system for dissolving the acetaminophen. The formulation is free of any ionizing agent and its solvent system includes water, polyethylene glycol, and polyvinylpyrrolidone that is 2-50% by weight and has a molecular weight of 2,000 to 1,500,000. Also disclosed is another acetaminophen formulation containing polyvinylpyrrolidone as high as 25-50% by weight.